| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR)
ARWR Technical Analysis
5
| As on 9th Jun 2023 ARWR SHARE Price closed @ 35.32 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 41.91 & Strong Sell for SHORT-TERM with Stoploss of 53.95 we also expect STOCK to react on Following IMPORTANT LEVELS. |
ARWRSHARE Price
| Open | 35.82 | Change | Price | % |
| High | 36.02 | 1 Day | -0.38 | -1.06 |
| Low | 35.08 | 1 Week | 0.91 | 2.64 |
| Close | 35.32 | 1 Month | 0.36 | 1.03 |
| Volume | 491700 | 1 Year | -34.78 | -49.61 |
| 52 Week High 70.53 | 52 Week Low 23.68 | ||||
NASDAQ USA Most Active Stocks
| TSLA | 244.40 | 4.06% |
| TTOO | 0.07 | -12.50% |
| SOFI | 8.18 | 0.74% |
| FFIE | 0.33 | 6.45% |
| PONO | 1.72 | 2.38% |
| AMD | 124.92 | 3.20% |
| IDEX | 0.06 | 0.00% |
| NKLA | 0.70 | 14.75% |
| AMZN | 123.43 | -0.66% |
| AAPL | 180.96 | 0.22% |
NASDAQ USA Top Gainers Stocks
NASDAQ USA Top Losers Stocks
| ARWR Daily Charts |
ARWR Intraday Charts |
Whats New @ Bazaartrend |
ARWR Free Analysis |
|
|
ARWR Important Levels Intraday
| RESISTANCE | 37.13 |
| RESISTANCE | 36.55 |
| RESISTANCE | 36.19 |
| RESISTANCE | 35.83 |
| SUPPORT | 34.81 |
| SUPPORT | 34.45 |
| SUPPORT | 34.09 |
| SUPPORT | 33.51 |
ARWR Forecast April 2024
| 4th UP Forecast | 68.97 |
| 3rd UP Forecast | 58.18 |
| 2nd UP Forecast | 51.51 |
| 1st UP Forecast | 44.84 |
| 1st DOWN Forecast | 25.8 |
| 2nd DOWN Forecast | 19.13 |
| 3rd DOWN Forecast | 12.46 |
| 4th DOWN Forecast | 1.67 |
ARWR Weekly Forecast
| 4th UP Forecast | 47.88 |
| 3rd UP Forecast | 43.85 |
| 2nd UP Forecast | 41.36 |
| 1st UP Forecast | 38.87 |
| 1st DOWN Forecast | 31.77 |
| 2nd DOWN Forecast | 29.28 |
| 3rd DOWN Forecast | 26.79 |
| 4th DOWN Forecast | 22.76 |
ARWR Forecast2024
| 4th UP Forecast | 127.64 |
| 3rd UP Forecast | 98.03 |
| 2nd UP Forecast | 79.73 |
| 1st UP Forecast | 61.43 |
| 1st DOWN Forecast | 9.21 |
| 2nd DOWN Forecast | -9.09 |
| 3rd DOWN Forecast | -27.39 |
| 4th DOWN Forecast | -57 |
Arrowhead Pharmaceuticals Inc ( NASDAQ USA Symbol : ARWR )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
ARWR Business Profile
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in Phase I/II clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in Phase I/II clinical trial to reduce production of angiopoietin-like protein 3; ARO-HSD, which is in Phase I/II clinical trial for treating liver diseases; ARO-ENaC, which is in Phase I/II clinical trial to reduce production of the epithelial sodium channel alpha subunit in the airways of the lung; ARO-Lung2 for the treatment of chronic obstructive pulmonary disorder; ARO-COV for the treatment of COVID-19 and other pulmonary-borne pathogens; and ARO-HIF2, which is in phase Ib for the treatment of clear cell renal cell carcinoma. It is also involved in the development of JNJ-3989, a subcutaneously administered RNAi therapeutic candidate to treat chronic hepatitis B virus infection; Olpasiran to reduce production of apolipoprotein A; and ARO-AMG1 for treating genetically validated cardiovascular target. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop ARO-JNJ1, ARO-JNJ2, and ARO-JNJ3 RNAi therapeutics for liver-expressed targets; and license and research collaboration agreement with Takeda Pharmaceuticals U.S.A., Inc. to develop RNAi therapeutic candidate. The company was formerly known as Arrowhead Research Corporation and changed its name to Arrowhead Pharmaceuticals, Inc. in April 2016. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California. Address: 177 East Colorado Boulevard, Pasadena, CA, United States, 91105
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service